Patient characteristics and outcomes according to sex
| Characteristic | Men (N = 37) | Women (N = 19) | p |
|---|---|---|---|
| Age (mean, std.) | 69.8 (11.2) | 77.0 (15.2) | 0.0299 |
| Preceding mRS (median) | 0 | 0 | 0.15 |
| Deep hemorrhage (basal ganglia, thalamus) (N = 36) | 27 (75%) | 9 (25%) | 0.056 |
| Lobar (N = 12) | 3 (25%) | 9 (75%) | 0.002 |
| Infratentorial hemorrhage (N = 8) | 7 (87.5%) | 1 (12.5%) | 0.17 |
| Neurosurgical evacuation (N = 3) | 2 (66.7%) | 1 (33.3%) | 0.74 |
| Smokers | 7 (19%) | 1 (5%) | 0.24 |
| Diabetes | 9 (24%) | 6 (32%) | 0.75 |
| Hypertension | 34 (92%) | 17 (89%) | 1.00 |
| Anticoagulation | 8 (22%) | 8 (42%) | 0.13 |
| Pre-existing epilepsy | 3 (8%) | 0 | 0.28 |
| Length of stay (median, days) | 6 | 6 | 0.88 |
| mRS at discharge (median, IQR) | 4 (2) | 4 (2) | 0.65 |
| mRS at three months (median, IQR) | 3 (3) | 2 (3) | 0.73 |
| Mean follow-up (years, std.) | 1.8 (1.0) | 1.6 (1.0) | 0.38 |
| Developed new epilepsy | 2 (5%) | 1 (5%) | 1.00 |
| Mean time to epilepsy (years, std.) | 0.25 (0.14) | 0.80 (0) | 1.00 |
| Died | 6 (16%) | 5 (26%) | 0.48 |
| Mean survival time (years, standard error) | 2.8 (0.19) | 2.3 (0.30) | 0.38 |
IQR: interquartile range; mRS: modified Rankin Scale; std.: standard deviation
JOTS: Conceptualization, Investigation, Data curation, Formal analysis, Methodology, Project administration, Supervision, Validation, Visualization, Writing—original draft, Writing—review & editing. JT: Investigation, Supervision, Writing—review & editing. JP, LB, M Hassan, M Heikkinen, AK, AM, AMS, and JW: Investigation, Writing—review & editing. AMK: Formal analysis, Writing—original draft, Writing—review & editing. All authors read and approved the submitted version.
Jussi O.T. Sipilä, who is the Editorial Board Member of Exploration of Neuroscience, had no involvement in the decision-making or the review process of this manuscript. Jussi O.T. Sipilä: Honoraria (Novartis), Congress attendance support (Lundbeck), Advisory Board (Sandoz, Boehringer-Ingelheim), Shareholder (Orion). Ayla Mehdiyeva: Congress attendance support (Sanofi). Mohamed Hassan: Congress attendance support (Merck). Johanna Willman: Congress attendance support (Orion). Anne-Mari Kantanen: Advisory board (Boehringer-Ingelheim, Astra-Zeneca), Congress Attendance support Astra Zeneca. All other authors declare that they have no conflicts of interest.
This study involves no direct contact (outside of normal healthcare procedures) with the patients, and ethical approval is therefore not required according to Finnish law.
This study involves no direct contact (outside of normal healthcare procedures) with the patients or publishing identifiable individual level information, and patient consent is therefore not required according to Finnish law.
Not applicable.
These data are subject to restrictions by Finnish law. Access can be applied for from Siun Sote (https://www.siunsote.fi/web/english/contact-information).
Not applicable.
© The Author(s) 2025.
Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.